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Abstract
Effects of synthetic neurotensin on the endocrine pancreas were studied in nine normal and six
hypophysectomized (10th to 14th day post-hypophysectomy) dogs. Synthetic neurotensin was ad-
ministered into the superior pancreaticoduodenal artery, and plasma insulin and glucagon concen-
trations were measured radioimmunologically. In normal dogs, ten microgram/kg neurotensin ad-
ministration brought about a mild hyperglycemic response and sharp and rapid increase of plasma
insulin and glucagon concentrations in the superior pancreaticoduodenal vein. A biphasic insulin
response was noted in the pancreatic vein. The results suggest that a large dose of neurotensin acts
directly on the endocrine pancreas causing secretion of these hormones. In hypophysectomized
dogs, basal levels of plasma insulin and glucagon were decreased and neurotensin had little effect
on the endocrine pancreas even with the administration of a large dose.
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Abstract. Effects of synthetic neurotensin on the endocrine pancreas
were studied in nine normal and six hypophysectomized (10th to 14th
day post-hypophysectomy) dogs. Synthetic neurotensin was administer-
ed into the superior pancreaticoduodenal artery, and plasma insulin and
glucagon concentrations were measured radioimmunologically. In nor-
mal dogs, ten pgjkg neurotensin administration brought about a mild
hyperglycemic response and sharp and rapid increase of plasma insulin
and glucagon concentrations in the superior pancreaticoduodenal vein.
A biphasic insulin response was noted in the pancreatic vein. The
results suggest that a large dose of neurotensin acts directly on the endo-
crine pancreas causing secretion of these hormones. In hypophysectom-
ized dogs, basal levels of plasma insulin and glucagon were decreased
and neurotensin had little effect on the endocrine pancreas even with
the administration of a large dose.
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A hypotensive peptide, neurotensin (1), isolated from bovine hypothalami,
has been found to have kinin-like biological activities, including vasodilatation
and cyanosis, a local increase in vascular permeability, and contraction of various
isolated smooth muscle preparations and relaxation of rat duodenum. Further-
more, neurotensin possesses other interesting biological properties, e. g., intra-
venenous injection of neurotensin in rats brings about an increase in plasma
ACTH levels (2), an elevation of plasma luteinizing hormone and follicle-stimu-
lating hormone levels (3), hyperglycemia (3-7) and hyperglucagonemia (5-7).
There are controversial reports concerning the effect of neurotensin on insulin
secretion. Brown et at. (5,6) reported that neurotensin reduced insulin levels in
the peripheral blood, but not in the portal blood in rats. Nagai and Frohman (7)
stated that neurotensin stimulated minimal insulin response in normal rats and
markedly enhanced insulin response in rats with adrenal autotransplantation.
This paper describes the effects of large doses of synthetic neurotensin on the
endocrine pancreas in normal and hypophysectomized dogs.
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MATERIALS AND METHODS
Nine healthy, adult mongrel dogs weighing 10 to 16 kg were fasted overnight.
The animals were anesthetized with sodium pentobarbital at 25 mg/kg BW. A
T-shaped tube was implanted in the superior pancreaticoduodenal (pancreatic)
artery 1 to 2 cm proximal from the junction of the right gastroepiploic artery for
injection of synthetic neurotensin. Synthetic neurotensin was obtained from
Protein Research Institute of Osaka University, Osaka, Japan. Another T-shaped
tube was implanted in the superior pancreaticoduodenal (pancreatic) vein. One
femoral vein was cannulated with polyethylene tubing. In order to observe the
effects of neurotensin on the endocrine pancreas of the hypophysectomized ani-
mals without any replacement therapy, the same surgical procedure was per-
formed on six hypophysectomized dogs on the 10th to 14th day after hypophy-
sectomy. Hypophysectomy was confirmed by postmortem examination after the
experiment in each dog.
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Fig. 1. Mild hyperglycemic response was observed after 10 ,ug/kg neurotensin injection
into the superior pancreaticoduodenal artery in normal dogs. Biphasic insulin response with
a rapid and sharp initial elevation and second significant elevation at 30 min post-injection
was noted in the superior pancreaticoduodenal vein. Significant differences between basal
and neurotensin induced blood glucose and insulin levels are denoted by @ P < 0.01 and
ep <0.05.
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A dose of 10 /lg/kg of synthetic neurotensin in 10 Ltg/ml physiological saline
was rapidly administered into the pancreatic artery. Blood pressure of the femo-
ral artery and impedance in the pancreatic tissue were determined by the method
of Tasaka and Akagi (8). Impedance change reflects blood flow in the pancreatic
tissue; decrease in the impedance indicates increase in the blood flow. Blood
samples were collected from the pancreatic vein and the femoral vein. Blood
glucose was determined by the glucose oxidase method. Plasma insulin (9) and
glucagon (10) were assayed radioimmunologically. Plasma cortisol was measured
by radioimmunoassay (11). The mean values and the standard errors of the
means were calculated. The Wilcoxon signed-rank test was employed for statisti-
cal analysis of the differences of means in paired samples. The Mann-Whitney
U test was used to determine statistical dIfferences for non-paired values.
RESULTS
Normal dogs. In a control study of 5 normal dogs, blood glucose, plasma
insulin and glucagon in pancreatic and femoral vein showed constant mean value
during the experiment after administration of physiological saline (one ml/kg)
into the pancreatic artery.
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Fig. 2. A sharp and prominent glucagon response was noted in the superior pancreati-
coduodenal and femoral vein immediately after neurotensin injection. Plasma glucagon
levels remained at significantly high levels during the test. Significant differences between
basal and neurotensin induced glucagon levels are denoted by @ P < 0.01 and. P < 0.05.
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Fig. 3. The upper figure shows change of blood pressure of the femoral artery after
10 ,ug/kg neurotensin administration into the superior pancreaticoduodenal artery in one dog.
The blood pressure was lowered to 40% of the initial value at 2 min and returned gradually
to the initial level at the end of the experiment. B. P.: blood pressure. The lower figure
shows impedance change of the pancreatic tissue after 10 ,ug/kg neurotensin administration
into the superior pancreaticoduodenal artery. Decreasing impedance is recorded as a down
ward deflection and indicates increasing blood flow. Calibration of 50 is shown on the right-
hand side. IMP: impedance.
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Fig. 4. Plasma cortisol level was rapidly increased after neurotensin adm S'istration and
reached a peak at 5 min, but the elevation is statistically not significant.
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The blood glucose level of the femoral vein was elevated to a peak with an
average increase of 114 % at 10 min after neurotensin administration (Fig. I).
A rapid and sharp insulin response was observed in pancreatic and femoral veins
immediately after neurotensin administration. A biphasic insulin response with
the second peak at 30 min was noted in the pancreatic vein. Neurotensin admin-
istration provoked a sharp and rapid secretory response of plasma glucagon in
the pancreatic vein (Fig. 2). Plasma glucagon levels in the pancreatic vein re-
mained significantly elevated with the nadir at 45 min. Plasma glucagon levels
in the femoral vein reached a peak at 10 min and remained at significant high
levels with the nadir at 60 min during the test. Blood pressure was lowered to
40 % of initial value at 2 min after neurotensin administration and returned
gradually to the initial level at the end of the experiment (Fig. 3). After a tiny
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Fig. 5. In hypophysectomized dogs, no significant hyperglycemia was observed after
10 pg/kg BW neurotensin injection. Basal insulin levels were suppressed and a small and
transient insulin response to neurotensin was followed by more lowered insulin level in the
superior pancreaticoduodenal vein. There was no definite elevation of the femoral insulin
level. Significant differences between basal and neurotensin induced blood glucose and insu-
lin levels are denoted by • P <0.05.
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and immediate decrease, impedance in the pancratic tissue transiently and sharp~
ly increased at 5 min after injection, and this was followed by a slow decrease for
20 min. The plasma cortisol level was elevated after neurotensin administration
but the change was not significant (Fig. 4).
Hypophysectomized dogs. The initial blood glucose level in hypophysectomized
dogs was decreased to 74% of the normal level and neurotensin administration
resulted in no significant elevation of blood glucose (Fig. 5). Basal levels of
plasma insulin in the pancreatic vein and femoral vein were lower than in the
normal dogs. A small insulin response was observed in the pancreatic vein at
5 min after injection and was followed by much lower levels at 30 to 60 min.
There was no increase of insulin in the femoral vein. The basal plasma glucagon
level in the pancreatic vein was lower and its response to neurotensin was blunted
(Fig. 6). An insignificant glucagon respone to neurotensin was noted in the
femoral vein.
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Fig. 6. Basal level of glucagon in the superior pancreaticoduodenal vein was slightly
suppressed in hypophysectomized dogs. Delayed and blunted glucagon response was observed
in the superior pancreaticoduodenal vein after neurotensin administration. Significant differ-
ences between basal and neurotensin induced glucagon levels are denoted by @P < 0.01.
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DISCUSSION
In the present study, a large amount of neurotensin was administered to
observe the pharmacological effect of the peptide on normal and hypophysectom-
ized dogs.
In normal dogs, blood glucose reached a peak at 1omin after injection of
neurotensin into the pancreatic artery. Neurotensin has been found to produce
a transient hyperglycemia within minutes after intravenous injection in anesthe-
tized rats (3, 4). There was a linear dose response relationship over the range of
20-200 p moles/l 00 g (glucose 18-145 mg/IOO ml) 15 min after injection. The
peptide caused a fall in liver glycogen and a 7-fold increase in the activities of
glycogen phosphorylase.
The present study showed that a large dose of neurotensin produced rapid
increases of plasma insulin and glucagon concentrations after administration into
the pancreatic artery. Insulin levels in the pancreatic vein showed a biphasic
increase. The mechanism of the biphasic insulin secretion of neurotensin is un-
known. In no respect was the increase found in plasma cortisol level statistically
significant in this study, but the second peak might be evoked by ACTH or corti-
costeroids stimulated by neurotensin (2). Blood flow which was reflected by
impedance of the pancreatic tissue decreased transiently for the first 10 min.
However, the net increase of insulin and glucagon output into the pancreatic vein
seem to be significant because of a prominent increase in the concentration of the
peptides. Neurotensin appeared more potent to inducing hyperglucagonemia in
this study. Our data suggest that neurotensin has a direct action on the endocrine
pancreas in anesthetized dogs.
It has been reported that hypophysectomized animals showed decreased
blood glucose and serum insulin levels (12-14) and increased serum glucagon
levels (14). Carraway and his colleagues (3) demonstrated that the hyper-
glycemic response in hypophysectomized rats (4 days after operation) was less
sensitive to neurotensin, perhaps as a consequence of their diminished liver glyco-
gen levels. The liver glycogen level as well as the hyperglycemic response were
partially restored by cortisone replacement indicating that the diminished re-
sponses were secondary effects following hypophysectomy but that the presence
of the pituitary was not required. Those investigations led to the conclusion that
liver glycogen might be subject to regulation by a mechanism that involved this
peptide. In the present study, there was no elevation of blood glucose after
administration of a large amount of neurotensin in hypophysectomized dogs.
Responses of insulin and glucagon secretion to neurotensin were also suppressed
as compared with those observed in normal dogs. There was no second peak
elevation of insulin in hypophysectomized dogs. This might be due to no secre-
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tion of ACTH and decreased response of corticosteroids after hypophysectomy.
Hypophysectomy resulted in a greater inhibitory .effect upon the endocrine pan-
creas.
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